The Vestibular Schwannoma (Acoustic Neuroma) drugs in development market research report provides comprehensive information on the therapeutics under development for Vestibular Schwannoma (Acoustic Neuroma), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Vestibular Schwannoma (Acoustic Neuroma). Buy the report here.

Smarter leaders trust GlobalData

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Vestibular Schwannoma (Acoustic Neuroma) and features dormant and discontinued products.

GlobalData tracks six drugs in development for Vestibular Schwannoma (Acoustic Neuroma) by six companies/universities/institutes. The top development phase for Vestibular Schwannoma (Acoustic Neuroma) is phase ii with three drugs in that stage. The Vestibular Schwannoma (Acoustic Neuroma) pipeline has five drugs in development by companies and one by universities/ institutes. Some of the companies in the Vestibular Schwannoma (Acoustic Neuroma) pipeline products market are: AstraZeneca, Millennium Pharmaceuticals and Novartis.

The key targets in the Vestibular Schwannoma (Acoustic Neuroma) pipeline products market include Dual Specificity Mitogen Activated Protein Kinase Kinase 2 (ERK Activator Kinase 2 or MAPK/ERK Kinase 2 or MAP2K2 or EC 2.7.12.2), Dual Specificity Mitogen Activated Protein Kinase Kinase 1 (ERK Activator Kinase 1 or MAPK/ERK Kinase 1 or MAP2K1 or EC 2.7.12.2), and Epidermal Growth Factor Receptor (Proto Oncogene c ErbB 1 or Receptor Tyrosine Protein Kinase erbB 1 or HER1 or ERBB1 or EGFR or EC 2.7.10.1).

The key mechanisms of action in the Vestibular Schwannoma (Acoustic Neuroma) pipeline product include Histone Deacetylase (HDAC or EC 3.5.1.98) Inhibitor with one drug in Phase 0. The Vestibular Schwannoma (Acoustic Neuroma) pipeline products include two routes of administration with the top ROA being Oral and two key molecule types in the Vestibular Schwannoma (Acoustic Neuroma) pipeline products market including Small Molecule, and Gene Therapy.

Vestibular Schwannoma (Acoustic Neuroma) overview

Vestibular schwannoma is a benign, slow-growing tumor that develops from the balance and hearing nerves. It is also called an acoustic neuroma/neurinoma/neurilemma and is mainly caused by overproduction of Schwann cells. It affects the hearing and balance nerves, causing unilateral or asymmetric hearing loss, tinnitus, and dizziness/loss of balance. It can be diagnosed by thorough ear examination and hearing and balance testing with the help of an audiogram, electronystagmography, and the auditory brainstem response (ABR) test. MRI scans can also help in early detection, determining location and size of acoustic neuroma in planning microsurgical removal. There are three options for managing a vestibular schwannoma: surgical removal, radiation, and observation. Alternative to surgical techniques, radiosurgery/radiotherapy (gamma knife) can be used to reduce the size of tumors.

For a complete picture of Vestibular Schwannoma (Acoustic Neuroma)’s pipeline drug market, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.